These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16737923)

  • 1. Interphase FISH for the detection of breakpoints in IG loci and chromosomal changes with adverse prognostic impact in multiple myeloma with normal karyotypes.
    Sáez B; Martín-Subero JI; Odero MD; Prosper F; Hernandez R; Cigudosa JC; Siebert R; Calasanz MJ
    Cancer Genet Cytogenet; 2006 Jun; 167(2):183-5. PubMed ID: 16737923
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of recurrent chromosomal breakpoints in multiple myeloma with complex karyotypes by combined G-banding, spectral karyotyping, and fluorescence in situ hybridization analyses.
    Sáez B; Martín-Subero JI; Largo C; Martín MC; Odero MD; Prosper F; Siebert R; Calasanz MJ; Cigudosa JC
    Cancer Genet Cytogenet; 2006 Sep; 169(2):143-9. PubMed ID: 16938572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection of complex chromosomal aberrations in patients with multiple myeloma using multiplex fluorescence in situ hybridization].
    Jiang YQ; Chen LJ; Zhu Y; Qiu HR; Wang R; Xu JR; Lu H; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Aug; 27(4):441-4. PubMed ID: 20677154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance.
    Schmidt-Wolf IG; Glasmacher A; Hahn-Ast C; Jüttner A; Schnurr T; Cremer F; Moehler T; Goldschmidt H; Busert B; Schubert R; Schwanitz G
    Cancer Genet Cytogenet; 2006 May; 167(1):20-5. PubMed ID: 16682281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent involvement of heterochromatic regions in multiple myeloma-a multicolor FISH study.
    Lange K; Gadzicki D; Schlegelberger B; Göhring G
    Leuk Res; 2010 Aug; 34(8):1002-6. PubMed ID: 20022374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined cytogenetic testing and fluorescence in situ hybridization analysis in the study of chronic lymphocytic leukemia and multiple myeloma.
    Wiktor A; Van Dyke DL
    Cancer Genet Cytogenet; 2004 Aug; 153(1):73-6. PubMed ID: 15325099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fluorescence in situ hybridization identifies complex chromosomal aberrations in multiple myeloma].
    Liu SY; Huang JW; Zhang J; Du HP; Jiang H; Li JY; Xue YQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec; 24(6):685-8. PubMed ID: 18067084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
    Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB;
    Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH.
    Cremer FW; Kartal M; Hose D; Bila J; Buck I; Bellos F; Raab MS; Brough M; Moebus A; Hager HD; Goldschmidt H; Moos M; Bartram CR; Jauch A
    Cancer Genet Cytogenet; 2005 Sep; 161(2):116-24. PubMed ID: 16102581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of standard prognostic factors with the deletion of 13q14 detected by interphase fluorescence in situ hybridization on separated and unseparated bone marrow cells in multiple myeloma].
    Smejkalová J; Vranová V; Oltová A; Kuglík P; Filková H; Heinigová J; Kovárová L; Adam Z; Krejcí M; Pour L; Büchler T; Svobodník A; Vostrejsová S; Kalábová V; Vorlícek J; Penka M; Hájek R
    Cas Lek Cesk; 2005; 144(7):483-8. PubMed ID: 16161543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
    Fonseca R; Harrington D; Oken MM; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Blood EA; Rajkumar SV; Kay NE; Van Ness B; Greipp PR
    Cancer Res; 2002 Feb; 62(3):715-20. PubMed ID: 11830525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High frequencies of chromosomal aberrations in multiple myeloma and monoclonal gammopathy of undetermined significance in direct chromosome preparation.
    Nilsson T; Lenhoff S; Rylander L; Höglund M; Turesson I; Mitelman F; Westin J; Johansson B
    Br J Haematol; 2004 Aug; 126(4):487-94. PubMed ID: 15287940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation of chromosomal aberrations with prognostic markers in multiple myeloma patients--a single institution study].
    Lee JW; Lee JK; Hong YJ; Hong SI; Chang YH
    Korean J Lab Med; 2008 Dec; 28(6):413-8. PubMed ID: 19127104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics.
    Bink K; Haralambieva E; Kremer M; Ott G; Beham-Schmid C; de Leval L; Peh SC; Laeng HR; Jütting U; Hutzler P; Quintanilla-Martinez L; Fend F
    Haematologica; 2008 Apr; 93(4):623-6. PubMed ID: 18326524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of 13q abnormalities in multiple myeloma using immunomagnetically selected plasma cells.
    Fiserová A; Hájek R; Holubová V; Büchler T; Sobotka J; Kovárová R; Musilová R; Bourková L; Buliková A; Mareschová I; Janácková Z; Váñová P; Kuglík P; Vorlícek J; Penka M
    Neoplasma; 2002; 49(5):300-6. PubMed ID: 12458327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of bone marrow involvement in malignant lymphoma using fluorescence in situ hybridization: possible utility in the detection of micrometastasis.
    Huh HJ; Min HC; Cho HI; Chae SL; Lee DS
    Cancer Genet Cytogenet; 2008 Oct; 186(1):1-5. PubMed ID: 18786435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent Cytogenetic Abnormalities in Multiple Myeloma.
    Chan NC; Chan NP
    Methods Mol Biol; 2017; 1541():295-302. PubMed ID: 27910031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis.
    Hardan I; Rothman R; Gelibter A; Cohen N; Shimoni A; Sokolovsky M; Reichart M; Ishoev G; Amariglio N; Rechavi G; Nagler A; Trakhtenbrot L
    Exp Hematol; 2004 Mar; 32(3):254-60. PubMed ID: 15003310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosome 1 abnormalities in multiple myeloma.
    Marzin Y; Jamet D; Douet-Guilbert N; Morel F; Le Bris MJ; Morice P; Abgrall JF; Berthou C; De Braekeleer M
    Anticancer Res; 2006; 26(2A):953-9. PubMed ID: 16619492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma.
    Kaufmann H; Krömer E; Nösslinger T; Weltermann A; Ackermann J; Reisner R; Bernhart M; Drach J
    Eur J Haematol; 2003 Sep; 71(3):179-83. PubMed ID: 12930318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.